Alchemab Appoints Ben Porter Brown Chief Medical Officer
Alchemab Therapeutics appointed Ben Porter-Brown, M.D., as chief medical officer as the company prepares to initiate a Phase I study of ATLX-2847, a prostaglandin dehydrogenase inhibitor for muscle atrophy, by year-end 2026. Porter-Brown joins…
